Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages

Fig. 2

Reduction of colon cancer cell proliferation, migration, and invasion capacities after the reduction of PCSK9 expression in vitro. a-c, Western blot. HCT116 and HT-29 cells were grown and transfected with PCSK9 siRNA or PCSK9 shRNA and then subjected to Western blot analysis of PCSK9 expression. The graph is quantified data of Western blots (n = 3). d and e, Trypan blue exclusion assay and CCK-8 assay. Knockdown of PCSK9 expression decreased the viability of HCT116 and HT-29 cells at day 4 after transient transfaction. f, CCK-8 assay. Knockdown of PCSK9 expression decreased the proliferation of stable transfected cells at day 4 after seeding. g-i, Wound-healing assay. HCT116 and HT-29 cells were grown and transiently transfected with PCSK9 or control siRNA and then subjected to the assay. The graph is the quantified data of the assay. The data showed that PCSK9 silence reduced tumor cell wound healing rates of HCT116 and HT-29. Magnification, × 40. j, Transwell assay. HCT116 and HT-29 cells were grown and transiently transfected with PCSK9 or control siRNA, and then subjected to the Transwell assay. The data revealed that PCSK9 knockdown inhibited migration of HCT116 and HT-29 cells. Magnification, × 200. k, Transwell invasion assay. HCT116 and HT-29 cells were grown and transiently transfected with PCSK9 or control siRNA, and then subjected to the Transwell assay. The data showed that PCSK9 knockdown inhibited the invasion of HCT116 and HT-29 cells. Magnification, × 200. Con, control cells without transfection; NC, negative control cells transfected with negative control siRNA; KD, knockdown of PCSK9 cells transfected with PCSK9 siRNA. ns, no significance; hs, hours; ds, days. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page